FasterCures praises efforts to modernize FDA drug review programs
This morning, U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb made an important announcement, introducing five guidance documents that focus on advancing treatments for neurological disorders, an area in which there is a vast unmet need and lack of understanding.
“FasterCures is honored to have participated in the groundbreaking work that led to the commissioner’s statement, and our team is eager to see progress toward treating the neurological conditions from which millions of patients suffer,” said Tanisha Carino, executive director of FasterCures, a center of the Milken Institute. “This announcement speaks volumes to the exciting changes afoot in the biomedical R&D world.”
FasterCures applauds the FDA’s efforts to streamline its drug regulatory programs and to utilize patient organizations as partners and experts in R&D. The guidance documents are evidence of a commitment to building a more efficient, collaborative process through which we can speed up and improve the medical research system.